New vaccine strategy might offer protection against pandemic influenza strains

May 18, 2009

A novel vaccine strategy using virus-like particles (VLPs) could provide stronger and longer-lasting influenza vaccines with a significantly shorter development and production time than current ones, allowing public health authorities to react more quickly in the event of a potential pandemic.

Ted Ross, Ph.D., an assistant professor at the University of Pittsburgh's Center for Vaccine Research, will present his laboratory's latest data on the efficacy of VLP vaccines for potential pandemic strains, such as H5N1 and 1918 influenza, today at the 109th General Meeting of the American Society for Microbiology in Philadelphia.

"Virus-like particles look just like a live virus, but they are hollow shells without a genome inside and they cannot reproduce," Ross explained. "Because they look like the virus, they evoke a more robust immune response against the real thing."

Ross and his colleagues have already made VLP vaccines that have been tested in early clinical trials and appear to provide complete protection against both the H5N1 avian influenza virus and the 1918 Spanish influenza virus.

"There is a debate in the influenza community about priming the human population for potential pandemic strains such as H5N1 or 1918," Ross said. "Some researchers advocate adding these strains to the annual flu vaccine. They might not match the next strain exactly, but could provide some of protection."

Others contend that it might be premature, as well as costly, to vaccinate people against a virus that may never emerge, he said.

The current injectable vaccine for seasonal influenza is a trivalent, inactivated vaccine. It consists of three different strains that are grown in eggs and then inactivated, or killed, by chemicals that break them into tiny pieces. Because they no longer look like the circulating virus, conventionally made vaccines strains do not elicit as strong an immune response as VLP vaccines. Because it is made with live, attenuated virus, the inhaled, mist-based vaccine can elicit a strong but can also increase the risk of side effects.

VLPs can be quickly and easily produced in several ways, including growing them in cell cultures or in plants. Also, if the genes in the disease virus are identified, then researchers can generate particles for a vaccine without an actual sample of the agent.

"The sequence for the recent H1N1 'swine flu' virus was online and available to scientists long before physical samples could be delivered," Dr. Ross noted. "It would have been possible to produce VLPs in quantity in as little as 12 weeks while conventional vaccines require physical samples of the virus and production can take approximately nine months."

One VLP-based vaccine already is on the market, namely the human papilloma (HPV) .

Source: American Society for Microbiology

Explore further: Top Japan lab dismisses ground-breaking stem cell study

add to favorites email to friend print save as pdf

Related Stories

Unusual flu vaccine is developed

Jun 14, 2006

U.S. scientists have used reverse genetics to develop an influenza virus with two key proteins on its surface derived from the H5N1 avian virus strain.

Bird flu vaccine protects people and pets

Oct 20, 2008

A single vaccine could be used to protect chickens, cats and humans against deadly flu pandemics, according to an article published in the November issue of the Journal of General Virology. The vaccine protects birds and ma ...

Recommended for you

Top Japan lab dismisses ground-breaking stem cell study

17 hours ago

Japan's top research institute on Friday hammered the final nail in the coffin of what was once billed as a ground-breaking stem cell study, dismissing it as flawed and saying the work could have been fabricated.

Research sheds light on what causes cells to divide

Dec 24, 2014

When a rapidly-growing cell divides into two smaller cells, what triggers the split? Is it the size the growing cell eventually reaches? Or is the real trigger the time period over which the cell keeps growing ...

Locking mechanism found for 'scissors' that cut DNA

Dec 24, 2014

Researchers at Johns Hopkins have discovered what keeps an enzyme from becoming overzealous in its clipping of DNA. Since controlled clipping is required for the production of specialized immune system proteins, ...

Scrapie could breach the species barrier

Dec 24, 2014

INRA scientists have shown for the first time that the pathogens responsible for scrapie in small ruminants (prions) have the potential to convert the human prion protein from a healthy state to a pathological ...

Extracting bioactive compounds from marine microalgae

Dec 24, 2014

Microalgae can produce high value health compounds like omega-3s , traditionally sourced from fish. With declining fish stocks, an alternative source is imperative. Published in the Pertanika Journal of Tr ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.